NIH Selects Northwell to Join Diabetic Foot Ulcer Consortium

Northwell Health has been selected to join the Diabetic Foot Consortium as a satellite site and awarded a grant by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The Diabetic Foot Consortium is led by a network of seven universities with satellite locations all working to drive clinical research. Northwell will serve as a satellite program and collaborate directly with the University of Michigan team. The NIDDK is part of the National Institutes of Health (NIH), the nation’s medical research agency.

Northwell’s $50,000 NIH grant will go toward refining wound care best practices and equity of care in the diabetic population. An estimated 37 million Americans are living with diabetes – many of them undiagnosed – and diabetic foot disease is a key factor that accounts for a measurable reduction in life expectancy.

“Diabetic foot ulcers are the leading cause of lower limb amputations in the United States today, which is why we’re excited to be part of the solution to such a chronic health problem,” said Alisha Oropallo, MD, a vascular surgeon and director of the Comprehensive Wound Healing Center and Hyperbarics at Northwell Health. “As a satellite member of the Diabetic Foot Consortium, Northwell will be able to conduct studies and tap into research to improve the lives of New Yorkers living with diabetic foot ulcers.”

Northwell’s Comprehensive Wound Healing Center and Hyperbarics, located at 1999 Marcus Ave., Suite M6, in Lake Success, NY, specializes in diabetic wound care. The center features a state-of-the-art vascular lab, a New York State-licensed tissue bank and diagnostic imaging that can assess microperfusion.

For more information or to make an appointment, call 516-233-3780.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”